| For: | Dong S, Wu XZ. Heparanase and hepatocellular carcinoma: Promoter or inhibitor? World J Gastroenterol 2010; 16(3): 306-311 [PMID: 20082475 DOI: 10.3748/wjg.v16.i3.306] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i3/306.htm |
| Number | Citing Articles |
| 1 |
WEI ZHANG, HONG CHAN, LOUWEI WEI, ZHONGMIAN PAN, JIEQING ZHANG, LI LI. Overexpression of heparanase in ovarian cancer and its clinical significance. Oncology Reports 2013; 30(5) doi: 10.3892/or.2013.2701
|
| 2 |
Cinzia Lanzi, Giuliana Cassinelli. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities. Biochemical Pharmacology 2020; 178 doi: 10.1016/j.bcp.2020.114084
|
| 3 |
Yasuo Tanaka, Ryosuke Tateishi, Kazuhiko Koike. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2018; 19(10) doi: 10.3390/ijms19103070
|
| 4 |
Shengjin Yu, Huiming Lv, Jinhui Zhang, He Zhang, Weiwei Ju, Yu Jiang, Lijuan Lin. Heparanase/Syndecan-1 Axis Regulates the Grade of Liver Cancer and Proliferative Ability of Hepatocellular Carcinoma Cells. Oncologie 2022; 24(3) doi: 10.32604/oncologie.2022.024882
|
| 5 |
Chanez Manseur, Hugo Groult, Manon Porta, Pierre-Edouard Bodet, Rachida Mersni-Achour, Raphaëlle Petit, Samir Ali-Moussa, Benjamin Musnier, Didier Le Cerf, Tony Varacavoudin, Oualid Haddad, Angela Sutton, Cíntia Emi Yanaguibashi Leal, Edilson Beserra Alencar-Filho, Jean-Marie Piot, Nicolas Bridiau, Thierry Maugard, Ingrid Fruitier-Arnaudin. A Screening Approach to Assess the Impact of Various Commercial Sources of Crude Marine λ-Carrageenan on the Production of Oligosaccharides with Anti-heparanase and Anti-migratory Activities. Marine Drugs 2023; 21(5) doi: 10.3390/md21050295
|
| 6 |
Keon Uk Park, Young-Su Seo, Yun-Han Lee, Jungwook Park, Ilseon Hwang, Koo Jeong Kang, Jehyun Nam, Sang-Woo Kim, Jin Young Kim. Altered microRNA expression profile in hepatitis B virus-related hepatocellular carcinoma. Gene 2015; 573(2) doi: 10.1016/j.gene.2015.07.053
|
| 7 |
Neel Thakkar, Tejabhiram Yadavalli, Dinesh Jaishankar, Deepak Shukla. Emerging Roles of Heparanase in Viral Pathogenesis. Pathogens 2017; 6(3) doi: 10.3390/pathogens6030043
|
| 8 |
John Whitelock, James Melrose. Heparan sulfate proteoglycans in healthy and diseased systems. WIREs Systems Biology and Medicine 2011; 3(6) doi: 10.1002/wsbm.149
|
| 9 |
Mohammed M.H. Al-Gayyar, Mohamed A. Ebrahim, Mohamed E.E. Shams. Measuring serum levels of glycosaminoglycans for prediction and using viscum fraxini-2 for treatment of patients with hepatocellular carcinoma. Journal of Pharmacy Research 2013; 7(7) doi: 10.1016/j.jopr.2013.07.016
|
| 10 |
Mohammed M.H. Al-Gayyar, Ahmed Abbas, Ahmed M. Hamdan. Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma. Biological Chemistry 2016; 397(3) doi: 10.1515/hsz-2015-0265
|
| 11 |
Mohammed A. F. Elewa, Mohammed M. Al-Gayyar, Mona F. Schaalan, Khaled H. Abd El Galil, Mohamed A. Ebrahim, Mamdouh M. El-Shishtawy. Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers. Clinical & Experimental Metastasis 2015; 32(5) doi: 10.1007/s10585-015-9721-6
|
| 12 |
Mohamed M Darweish, Ahmed Abbas, Mohamed A Ebrahim, Mohammed M H Al-Gayyar. Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway. Journal of Pharmacy and Pharmacology 2014; 66(7) doi: 10.1111/jphp.12229
|
| 13 |
Yiyuan Yang, Fengyan Yuan, Huiqin Zhou, Jing Quan, Chongyang Liu, Yi Wang, Fen Xiao, Qiao Liu, Jie Liu, Yujing Zhang, Xing Yu. Potential roles of heparanase in cancer therapy: Current trends and future direction. Journal of Cellular Physiology 2023; 238(5) doi: 10.1002/jcp.30995
|